Universal Beteiligungs und Servicegesellschaft mbH Buys 6,095 Shares of ResMed Inc. $RMD

Universal Beteiligungs und Servicegesellschaft mbH raised its stake in ResMed Inc. (NYSE:RMD) by 6.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 105,621 shares of the medical equipment provider’s stock after purchasing an additional 6,095 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.07% of ResMed worth $25,499,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. SJS Investment Consulting Inc. raised its position in shares of ResMed by 1,433.3% during the third quarter. SJS Investment Consulting Inc. now owns 92 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 86 shares during the last quarter. Imprint Wealth LLC acquired a new stake in ResMed during the third quarter worth about $26,000. WFA of San Diego LLC acquired a new stake in ResMed during the second quarter worth about $26,000. ORG Partners LLC increased its stake in ResMed by 181.6% during the fourth quarter. ORG Partners LLC now owns 107 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 69 shares during the period. Finally, Sunbelt Securities Inc. bought a new position in ResMed during the third quarter valued at about $31,000. 54.98% of the stock is currently owned by institutional investors and hedge funds.

ResMed Stock Performance

ResMed stock opened at $219.73 on Friday. The firm has a market capitalization of $32.01 billion, a P/E ratio of 21.73, a P/E/G ratio of 1.46 and a beta of 0.93. The stock has a fifty day moving average price of $237.17 and a two-hundred day moving average price of $248.86. ResMed Inc. has a 52-week low of $216.68 and a 52-week high of $293.81. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.06 and a quick ratio of 2.32.

ResMed (NYSE:RMD) last issued its earnings results on Friday, January 30th. The medical equipment provider reported $2.81 EPS for the quarter, beating the consensus estimate of $2.68 by $0.13. The company had revenue of $1.42 billion for the quarter, compared to the consensus estimate of $1.40 billion. ResMed had a net margin of 27.53% and a return on equity of 25.20%. The firm’s revenue for the quarter was up 11.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.43 EPS. As a group, analysts anticipate that ResMed Inc. will post 11.05 EPS for the current fiscal year.

ResMed Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 19th. Shareholders of record on Thursday, February 12th were given a $0.60 dividend. The ex-dividend date was Thursday, February 12th. This represents a $2.40 dividend on an annualized basis and a yield of 1.1%. ResMed’s payout ratio is 23.74%.

Analyst Upgrades and Downgrades

RMD has been the subject of a number of research reports. Robert W. Baird set a $281.00 price objective on ResMed in a research report on Friday, January 30th. KeyCorp restated an “overweight” rating and set a $302.00 price objective on shares of ResMed in a research report on Friday, January 30th. Evercore set a $255.00 target price on ResMed and gave the company an “outperform” rating in a research note on Monday, April 13th. JPMorgan Chase & Co. began coverage on ResMed in a research report on Wednesday, April 15th. They issued an “overweight” rating for the company. Finally, Stifel Nicolaus lifted their price target on shares of ResMed from $260.00 to $265.00 and gave the stock a “hold” rating in a research note on Friday, January 30th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, ResMed has an average rating of “Moderate Buy” and an average price target of $295.64.

Insider Activity

In other news, Director Peter C. Farrell sold 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $225.00, for a total transaction of $450,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michael J. Farrell sold 4,991 shares of ResMed stock in a transaction that occurred on Tuesday, April 7th. The shares were sold at an average price of $225.50, for a total transaction of $1,125,470.50. Following the completion of the transaction, the chief executive officer owned 466,223 shares of the company’s stock, valued at $105,133,286.50. This trade represents a 1.06% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 21,023 shares of company stock worth $5,230,857 over the last ninety days. Insiders own 0.65% of the company’s stock.

ResMed Profile

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.